High-dose chemotherapy for solid tumors: results of the EBMT.
暂无分享,去创建一个
Ruth Ladenstein | Serge Leyvraz | Jonathan Ledermann | J. Ledermann | M. Marangolo | S. Leyvraz | J. Crown | C. Dazzi | R. Ladenstein | John Crown | G. Rosti | Claudio Dazzi | P. Ferrante | Giovanni Rosti | Patrizia Ferrante | Ewa Koscileniak | Anna Cariello | Maurizio Marangolo | A. Cariello | Ewa Koscileniak
[1] M. Marangolo,et al. Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] N. Schmitz,et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998 , 1998, Bone Marrow Transplantation.
[3] D. Frappaz,et al. Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Hortobagyi,et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Armitage,et al. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. , 1999, JAMA.
[6] R. Motzer,et al. Testicular germ-cell cancer. , 1997, The New England journal of medicine.
[7] J. Peterse,et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement , 1998, The Lancet.
[8] Terry L. Smith,et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. , 2000, Journal of the National Cancer Institute.
[9] R. Theriault,et al. High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study , 2000, The Lancet.
[10] A Kramar,et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Smith,et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Dose and timing : the pillars of successful chemotherapy , 1998 .
[13] A. Luini,et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Gratwohl,et al. Blood and marrow transplantation activity in Europe 1995 , 1997, Bone Marrow Transplantation.
[15] L. Seymour,et al. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] W. Bezwoda. Randomised controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer , 1999 .
[17] T. Klingebiel,et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. , 1997, European journal of cancer.
[18] A. Gratwohl,et al. Blood and marrow transplantation activity in Europe 1997 , 1999, Bone Marrow Transplantation.
[19] A. Gratwohl,et al. Hematopoietic precursor cell transplants in Europe: activity in 1994. Report from the European Group for Blood and Marrow Transplantation (EBMT). , 1996, Bone marrow transplantation.
[20] G. Bonadonna,et al. Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] P. Richardson,et al. Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Armitage,et al. Reviews and Notes: Oncology: High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells , 1992, Annals of Internal Medicine.
[23] J. Machiels,et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] G. Hortobagyi,et al. High-Dose Chemotherapy in Breast Cancer , 1991 .
[25] S. Martino,et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. , 2000, The New England journal of medicine.
[26] R. Storb,et al. Mini-allografts: ongoing trials in humans , 2000, Bone Marrow Transplantation.
[27] J. Armitage,et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] C. Gisselbrecht,et al. Dose intensive therapy in breast cancer. , 1992, Bone marrow transplantation.
[29] G. Rosner,et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.